Investigational drug · Phase 3
Efimosfermin
Also called: BOS-580
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
6 still active
All registered trials
9
Any phase or sponsor naming "Efimosfermin"
First trial start
2021
Sep 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Efimosfermin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-alcoholic Fatty Liver Disease
- Metabolic Dysfunction-associated Steatohepatitis
- Liver Diseases, Alcoholic
- Metabolic Dysfunction-Associated Steatohepatitis
- Nonalcoholic Steatohepatitis (NASH)
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Efimosfermin" as an intervention, largest first.
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07701993 · 1,740 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 23, 2033
Drug: Efimosfermin alfa; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Little Rock, Arkansas; Folsom, California; Montclair, California · 37 sites in all
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221188 · 1,250 participants (planned) · Start Dec 12, 2025 · Primary completion Mar 24, 2028
Drug: Efimosfermin Alfa; Placebo · For: Non-alcoholic Fatty Liver Disease
Sites: Arcadia, California; Covina, California; Los Angeles, California · 66 sites in all
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221227 · 1,200 participants (planned) · Start Oct 24, 2025 · Primary completion Mar 29, 2028
Drug: Efimosfermin alfa; Efimosfermin alfa and 1 more · For: Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Tucson, Arizona; Little Rock, Arkansas · 91 sites in all
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07704892 · 380 participants (planned) · Start Jul 22, 2026 · Primary completion Oct 16, 2030
Drug: Efimosfermin alfa; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Little Rock, Arkansas; Arcadia, California; Arroyo Grande, California · 39 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07791043 · 274 participants (planned) · Start Aug 31, 2026 · Primary completion Aug 11, 2028
Drug: Efimosfermin alfa; Placebo · For: Liver Diseases, Alcoholic
Sites: Chandler, Arizona; Miami Lakes, Florida; Topeka, Kansas · 17 sites in all
- A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an ExtensionPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04880031 · 231 participants · Start Sep 30, 2021 · Primary completion Oct 27, 2025
Drug: Efimosfermin; Placebo · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Birmingham, Alabama; Chandler, Arizona; Peoria, Arizona · 48 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06920043 · 42 participants (planned) · Start Apr 9, 2025 · Primary completion Jul 3, 2028
Drug: Efimosfermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Mesa, Arizona; Tucson, Arizona · 30 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07358546 · 32 participants (planned) · Start Mar 13, 2026 · Primary completion Oct 13, 2027
Drug: Efimosfermin alfa · For: Non-alcoholic Fatty Liver Disease
Sites: Rialto, California; Miami Lakes, Florida; Tampa, Florida · 5 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07335198 · 30 participants · Start Mar 5, 2026 · Primary completion Aug 13, 2026
Drug: Efimosfermin alfa; Placebo · For: Non-alcoholic Fatty Liver Disease
Sites: Auckland, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- The use of FGF21 analogues in MASH and MASH cirrhosis - metabolic master regulators or liver-specific mechanisms?
Holleboom AG, Schattenberg JM · JHEP Rep 2026
- MASLD: Established Knowledge and Emerging Directions - Guideline Updates.
Roeb E, Geier A · Z Gastroenterol 2026
- Efimosfermin, a Fibroblast Growth Factor 21 Analogue for Metabolic Dysfunction-Associated Steatohepatitis.
Mullish BH · Gastroenterology 2026
- Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.
Alamgir M, Sohal A, Kowdley KV · Drug Des Devel Ther 2026
- Once-monthly efimosfermin for non-cirrhotic MASH.
Valenti L, Periti G · Lancet 2026
- Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
Noureddin M, Kowdley KV, Odrljin T, et al. · Lancet 2026
Also in development for Non-alcoholic Fatty Liver Disease
- GSK4532990Phase 23 trials
GSK · Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic, Nonalcoholic Fatty Liver Disease
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.